Deletion of Sphingosine Kinase 2 Attenuates Acute Kidney Injury in Mice with Hemolytic-Uremic Syndrome
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147683 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Tina Müller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, 07743 Jena, Germany. Hauptthemen laut MEDLINE: Phosphotransferases (Alcohol Group Acceptor), Acute Kidney Injury, Hemolytic-Uremic Syndrome, Mice, Knockout. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Ministry of Education and Research.
Abstract (Originalsprache)
Typical hemolytic uremic syndrome (HUS) can occur as a severe systemic complication of infections with Shiga toxin (Stx)-producing Escherichia coli. Its pathology can be induced by Stx types, resulting in toxin-mediated damage to renal barriers, inflammation, and the development of acute kidney injury (AKI). Two sphingosine kinase (SphK) isozymes, SphK1 and SphK2, have been shown to be involved in barrier maintenance and renal inflammatory diseases. Therefore, we sought to determine their role in the pathogenesis of HUS. Experimental HUS was induced by the repeated administration of Stx2 in wild-type (WT) and SphK1 (SphK1−/−) or SphK2 (SphK2−/−) null mutant mice. Disease severity was evaluated by assessing clinical symptoms, renal injury and dysfunction, inflammatory status and sphingolipid levels on day 5 of HUS development. Renal inflammation and injury were found to be attenuated in the SphK2−/− mice, but exacerbated in the SphK1−/− mice compared to the WT mice. The divergent outcome appeared to be associated with oppositely altered sphingolipid levels. This study represents the first description of the distinct roles of SphK1−/− and SphK2−/− in the pathogenesis of HUS. The identification of sphingolipid metabolism as a potential target for HUS therapy represents a significant advance in the field of HUS research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, 07743 Jena, Germany.
- ZIK Septomics Research Center, Jena University Hospital, 07743 Jena, Germany.
- Center for Molecular Biomedicine (CMB) and Center for Sepsis Control and Care (CSCC), Jena University Hospital, 07743 Jena, Germany.
- Center for Sepsis Control and Care (CSCC), Jena University Hospital, 07743 Jena, Germany.
ORCID-Profile: Markus H Gräler, Sina M Coldewey
Förderung
- Federal Ministry of Education and Research
Zitieren
APA
Müller, T., Krieg, N., Lange-Polovinkin, A. I., Wissuwa, B., Gräler, M. H., Dennhardt, S., & Coldewey, S. M. (2024). Deletion of Sphingosine Kinase 2 Attenuates Acute Kidney Injury in Mice with Hemolytic-Uremic Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147683
Vancouver
Müller T, Krieg N, Lange-Polovinkin AI, Wissuwa B, Gräler MH, Dennhardt S, et al. Deletion of Sphingosine Kinase 2 Attenuates Acute Kidney Injury in Mice with Hemolytic-Uremic Syndrome. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147683
BibTeX
@article{Mller2024,
author = {Müller, Tina and Krieg, Nadine and Lange-Polovinkin, Antonia I and Wissuwa, Bianka and Gräler, Markus H and Dennhardt, Sophie and Coldewey, Sina M},
title = {Deletion of Sphingosine Kinase 2 Attenuates Acute Kidney Injury in Mice with Hemolytic-Uremic Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147683}
}
EUVIMED